Series stock is trading -26.24% below its average target price of $20.63 after marking a 7.9% during today's morning session. Analysts are giving the Large-Cap Specialty Chemicals company an average rating of buy and target prices ranging from $17.0 to $26.0 per share.
The stock has an average amount of shares sold short at 2.4%, and a short ratio of 0.82. At 0.04%, the company's rate of insider ownership does not indicate that management is heavily invested in the corporation. Finally, we also note that a significant number of institutional investors are invested in the stock, with 101.2% of Series's shares being owned by this investor type.
Institutions Invested in Series
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-06-30 | Vanguard Group Inc | 12% | 233,246,267 | $3,551,174,504 |
| 2025-06-30 | Price (T.Rowe) Associates Inc | 9% | 168,041,407 | $2,558,430,485 |
| 2025-06-30 | Blackrock Inc. | 8% | 147,568,662 | $2,246,732,935 |
| 2025-06-30 | State Street Corporation | 6% | 115,021,218 | $1,751,198,087 |
| 2025-06-30 | FMR, LLC | 5% | 99,549,125 | $1,515,635,466 |
| 2025-06-30 | Massachusetts Financial Services Co. | 5% | 91,215,505 | $1,388,756,098 |
| 2025-06-30 | Geode Capital Management, LLC | 3% | 49,001,887 | $746,053,748 |
| 2025-06-30 | Wellington Management Group, LLP | 2% | 46,372,095 | $706,015,164 |
| 2025-06-30 | Franklin Resources, Inc. | 2% | 33,269,205 | $506,523,658 |
| 2025-06-30 | Bank Of New York Mellon Corporation | 2% | 31,614,330 | $481,328,186 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Series.
